Omalizumab to Treat Eosinophilic Gastroenteritis

NCT00084097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Gastroenteritis

Interventions

DRUG: Omalizumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)